Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes

Vijay Jayagopal, Eric S. Kilpatrick, Paul E. Jennings, David A. Hepburn, Stephen Atkin

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

OBJECTIVE - Individuals with type 2 diabetes are particularly vulnerable to cardiovascular disease. Insulin resistance is a major determinant of this increased risk and is a potential therapeutic target. This study was undertaken to establish the natural biological variation of insulin resistance in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS - The biological variation of insulin resistance was assessed by measuring insulin resistance at 4-day intervals on 10 consecutive occasions in 12 postmenopausal women with diet-controlled type 2 diabetes and in 11 weight- and age-matched postmenopausal women without type 2 diabetes. Insulin resistance was derived using the homeostasis model assessment for insulin resistance (HOMA-IR) method. RESULTS - The distribution of HOMA-IR was log Gaussian in the type 2 diabetic study group and Gaussian in the control group. The HOMA-IR in the type 2 diabetic group was significantly greater than that of the control group (mean ± SD: 4.33 ± 2.3 vs. 2.11 ± 0.79 units, P = 0.001). After accounting for analytical variation, the mean intraindividual variation was also substantially greater in the type 2 diabetic group than in the control group (mean 1.05 vs. 0.15, P = 0.001). Consequently, at any level of HOMA-IR, a subsequent sample must increase by >90% or decrease by >47% to be considered significantly different from the first. CONCLUSIONS - HOMA-IR is significantly greater and more variable for individuals with type 2 diabetes. Therefore, this inherent variability needs to be accounted for in studies evaluating therapeutic reduction of HOMA-IR in this group.

Original languageEnglish
Pages (from-to)2022-2025
Number of pages4
JournalDiabetes Care
Volume25
Issue number11
DOIs
Publication statusPublished - Nov 2002
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Insulin Resistance
Homeostasis
Control Groups
Research Design
Cardiovascular Diseases
Diet
Weights and Measures
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes. / Jayagopal, Vijay; Kilpatrick, Eric S.; Jennings, Paul E.; Hepburn, David A.; Atkin, Stephen.

In: Diabetes Care, Vol. 25, No. 11, 11.2002, p. 2022-2025.

Research output: Contribution to journalArticle

Jayagopal, Vijay ; Kilpatrick, Eric S. ; Jennings, Paul E. ; Hepburn, David A. ; Atkin, Stephen. / Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes. In: Diabetes Care. 2002 ; Vol. 25, No. 11. pp. 2022-2025.
@article{76588c5e56c6461c9429fd511a8b90c9,
title = "Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes",
abstract = "OBJECTIVE - Individuals with type 2 diabetes are particularly vulnerable to cardiovascular disease. Insulin resistance is a major determinant of this increased risk and is a potential therapeutic target. This study was undertaken to establish the natural biological variation of insulin resistance in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS - The biological variation of insulin resistance was assessed by measuring insulin resistance at 4-day intervals on 10 consecutive occasions in 12 postmenopausal women with diet-controlled type 2 diabetes and in 11 weight- and age-matched postmenopausal women without type 2 diabetes. Insulin resistance was derived using the homeostasis model assessment for insulin resistance (HOMA-IR) method. RESULTS - The distribution of HOMA-IR was log Gaussian in the type 2 diabetic study group and Gaussian in the control group. The HOMA-IR in the type 2 diabetic group was significantly greater than that of the control group (mean ± SD: 4.33 ± 2.3 vs. 2.11 ± 0.79 units, P = 0.001). After accounting for analytical variation, the mean intraindividual variation was also substantially greater in the type 2 diabetic group than in the control group (mean 1.05 vs. 0.15, P = 0.001). Consequently, at any level of HOMA-IR, a subsequent sample must increase by >90{\%} or decrease by >47{\%} to be considered significantly different from the first. CONCLUSIONS - HOMA-IR is significantly greater and more variable for individuals with type 2 diabetes. Therefore, this inherent variability needs to be accounted for in studies evaluating therapeutic reduction of HOMA-IR in this group.",
author = "Vijay Jayagopal and Kilpatrick, {Eric S.} and Jennings, {Paul E.} and Hepburn, {David A.} and Stephen Atkin",
year = "2002",
month = "11",
doi = "10.2337/diacare.25.11.2022",
language = "English",
volume = "25",
pages = "2022--2025",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes

AU - Jayagopal, Vijay

AU - Kilpatrick, Eric S.

AU - Jennings, Paul E.

AU - Hepburn, David A.

AU - Atkin, Stephen

PY - 2002/11

Y1 - 2002/11

N2 - OBJECTIVE - Individuals with type 2 diabetes are particularly vulnerable to cardiovascular disease. Insulin resistance is a major determinant of this increased risk and is a potential therapeutic target. This study was undertaken to establish the natural biological variation of insulin resistance in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS - The biological variation of insulin resistance was assessed by measuring insulin resistance at 4-day intervals on 10 consecutive occasions in 12 postmenopausal women with diet-controlled type 2 diabetes and in 11 weight- and age-matched postmenopausal women without type 2 diabetes. Insulin resistance was derived using the homeostasis model assessment for insulin resistance (HOMA-IR) method. RESULTS - The distribution of HOMA-IR was log Gaussian in the type 2 diabetic study group and Gaussian in the control group. The HOMA-IR in the type 2 diabetic group was significantly greater than that of the control group (mean ± SD: 4.33 ± 2.3 vs. 2.11 ± 0.79 units, P = 0.001). After accounting for analytical variation, the mean intraindividual variation was also substantially greater in the type 2 diabetic group than in the control group (mean 1.05 vs. 0.15, P = 0.001). Consequently, at any level of HOMA-IR, a subsequent sample must increase by >90% or decrease by >47% to be considered significantly different from the first. CONCLUSIONS - HOMA-IR is significantly greater and more variable for individuals with type 2 diabetes. Therefore, this inherent variability needs to be accounted for in studies evaluating therapeutic reduction of HOMA-IR in this group.

AB - OBJECTIVE - Individuals with type 2 diabetes are particularly vulnerable to cardiovascular disease. Insulin resistance is a major determinant of this increased risk and is a potential therapeutic target. This study was undertaken to establish the natural biological variation of insulin resistance in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS - The biological variation of insulin resistance was assessed by measuring insulin resistance at 4-day intervals on 10 consecutive occasions in 12 postmenopausal women with diet-controlled type 2 diabetes and in 11 weight- and age-matched postmenopausal women without type 2 diabetes. Insulin resistance was derived using the homeostasis model assessment for insulin resistance (HOMA-IR) method. RESULTS - The distribution of HOMA-IR was log Gaussian in the type 2 diabetic study group and Gaussian in the control group. The HOMA-IR in the type 2 diabetic group was significantly greater than that of the control group (mean ± SD: 4.33 ± 2.3 vs. 2.11 ± 0.79 units, P = 0.001). After accounting for analytical variation, the mean intraindividual variation was also substantially greater in the type 2 diabetic group than in the control group (mean 1.05 vs. 0.15, P = 0.001). Consequently, at any level of HOMA-IR, a subsequent sample must increase by >90% or decrease by >47% to be considered significantly different from the first. CONCLUSIONS - HOMA-IR is significantly greater and more variable for individuals with type 2 diabetes. Therefore, this inherent variability needs to be accounted for in studies evaluating therapeutic reduction of HOMA-IR in this group.

UR - http://www.scopus.com/inward/record.url?scp=0036834536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036834536&partnerID=8YFLogxK

U2 - 10.2337/diacare.25.11.2022

DO - 10.2337/diacare.25.11.2022

M3 - Article

VL - 25

SP - 2022

EP - 2025

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -